STATEMENT OF INVESTMENTS
BNY Mellon Small/Mid Cap Growth Fund
June 30, 2024 (Unaudited)
| | | | | | | |
|
Description | | | | Shares | | Value ($) | |
Common Stocks - 96.2% | | | | | |
Capital Goods - 10.4% | | | | | |
AAON, Inc. | | | | 135,911 | a | 11,856,875 | |
Axon Enterprise, Inc. | | | | 75,496 | b | 22,213,943 | |
Builders FirstSource, Inc. | | | | 109,906 | b | 15,212,089 | |
Curtiss-Wright Corp. | | | | 68,434 | | 18,544,245 | |
Fluor Corp. | | | | 484,861 | b | 21,115,697 | |
Hubbell, Inc. | | | | 57,182 | | 20,898,877 | |
SiteOne Landscape Supply, Inc. | | | | 170,744 | a,b | 20,730,029 | |
Zurn Elkay Water Solutions Corp. | | | | 332,876 | | 9,786,554 | |
| | | | 140,358,309 | |
Commercial & Professional Services - 1.0% | | | | | |
CACI International, Inc., Cl. A | | | | 30,864 | b | 13,275,532 | |
Consumer Discretionary Distribution & Retail - 5.2% | | | | | |
Burlington Stores, Inc. | | | | 57,657 | b | 13,837,680 | |
Chewy, Inc., Cl. A | | | | 424,587 | b | 11,565,750 | |
Ollie's Bargain Outlet Holdings, Inc. | | | | 298,029 | b | 29,257,507 | |
Pool Corp. | | | | 51,730 | | 15,898,181 | |
| | | | 70,559,118 | |
Consumer Durables & Apparel - 1.3% | | | | | |
Lululemon Athletica, Inc. | | | | 57,997 | b | 17,323,704 | |
Consumer Services - 4.1% | | | | | |
Dutch Bros, Inc., Cl. A | | | | 506,135 | b | 20,953,989 | |
European Wax Center, Inc., Cl. A | | | | 267,721 | a,b | 2,658,470 | |
Planet Fitness, Inc., Cl. A | | | | 442,307 | b | 32,549,372 | |
| | | | 56,161,831 | |
Energy - 6.6% | | | | | |
Antero Resources Corp. | | | | 462,394 | b | 15,087,916 | |
Cactus, Inc., Cl. A | | | | 273,484 | a | 14,423,546 | |
EQT Corp. | | | | 861,754 | | 31,867,663 | |
Oceaneering International, Inc. | | | | 645,228 | b | 15,266,095 | |
PBF Energy, Inc., Cl. A | | | | 290,241 | | 13,356,891 | |
| | | | 90,002,111 | |
Financial Services - 4.9% | | | | | |
AvidXchange Holdings, Inc. | | | | 1,087,506 | a,b | 13,115,322 | |
Block, Inc. | | | | 206,297 | b | 13,304,094 | |
Flywire Corp. | | | | 411,806 | b | 6,749,500 | |
Morningstar, Inc. | | | | 68,457 | | 20,253,003 | |
Tradeweb Markets, Inc., Cl. A | | | | 121,240 | | 12,851,440 | |
| | | | 66,273,359 | |
Food, Beverage & Tobacco - 5.5% | | | | | |
Celsius Holdings, Inc. | | | | 725,066 | b | 41,394,018 | |
Freshpet, Inc. | | | | 252,582 | a,b | 32,681,585 | |
| | | | 74,075,603 | |
Health Care Equipment & Services - 12.6% | | | | | |
Align Technology, Inc. | | | | 113,770 | b | 27,467,491 | |
STATEMENT OF INVESTMENTS (Unaudited) (continued)
| | | | | | | |
|
Description | | | | Shares | | Value ($) | |
Common Stocks - 96.2% (continued) | | | | | |
Health Care Equipment & Services - 12.6% (continued) | | | | | |
DexCom, Inc. | | | | 252,745 | b | 28,656,228 | |
Guardant Health, Inc. | | | | 502,271 | b | 14,505,587 | |
Inspire Medical Systems, Inc. | | | | 278,434 | a,b | 37,262,822 | |
iRhythm Technologies, Inc. | | | | 150,880 | b | 16,240,723 | |
Outset Medical, Inc. | | | | 221,406 | a,b | 852,413 | |
Privia Health Group, Inc. | | | | 764,963 | a,b | 13,295,057 | |
PROCEPT BioRobotics Corp. | | | | 82,282 | b | 5,026,607 | |
R1 RCM, Inc. | | | | 661,525 | b | 8,308,754 | |
TransMedics Group, Inc. | | | | 123,829 | b | 18,651,124 | |
| | | | 170,266,806 | |
Household & Personal Products - .2% | | | | | |
Oddity Tech Ltd., Cl. A | | | | 83,989 | a,b | 3,297,408 | |
Media & Entertainment - 7.2% | | | | | |
Liberty Media Corp-Liberty Formula One, Cl. C | | | | 273,914 | b | 19,677,982 | |
Live Nation Entertainment, Inc. | | | | 195,711 | b | 18,345,949 | |
Pinterest, Inc., Cl. A | | | | 575,748 | | 25,373,214 | |
Reddit, Inc., Cl. A | | | | 431,723 | a,b | 27,582,783 | |
Roblox Corp., Cl. A | | | | 180,328 | b | 6,710,005 | |
| | | | 97,689,933 | |
Pharmaceuticals, Biotechnology & Life Sciences - 15.4% | | | | | |
Ascendis Pharma A/S, ADR | | | | 65,719 | b | 8,962,757 | |
Autolus Therapeutics PLC | | | | 1,234,107 | b | 4,294,692 | |
Bio-Techne Corp. | | | | 337,231 | | 24,162,601 | |
Denali Therapeutics, Inc. | | | | 308,361 | b | 7,160,142 | |
GRAIL, Inc. | | | | 21,453 | b | 329,733 | |
Illumina, Inc. | | | | 128,723 | b | 13,436,107 | |
Insmed, Inc. | | | | 422,124 | b | 28,282,308 | |
Natera, Inc. | | | | 244,386 | b | 26,464,560 | |
Pacific Biosciences of California, Inc. | | | | 3,186,497 | a,b | 4,365,501 | |
Repligen Corp. | | | | 230,219 | a,b | 29,021,407 | |
Sarepta Therapeutics, Inc. | | | | 230,226 | b | 36,375,708 | |
Twist Bioscience Corp. | | | | 259,717 | b | 12,798,854 | |
Ultragenyx Pharmaceutical, Inc. | | | | 314,540 | b | 12,927,594 | |
| | | | 208,581,964 | |
Real Estate Management & Development - 2.6% | | | | | |
CoStar Group, Inc. | | | | 476,792 | b | 35,349,359 | |
Semiconductors & Semiconductor Equipment - 4.1% | | | | | |
FormFactor, Inc. | | | | 342,467 | b | 20,729,528 | |
Onto Innovation, Inc. | | | | 56,767 | b | 12,463,763 | |
Rambus, Inc. | | | | 388,033 | b | 22,800,819 | |
| | | | 55,994,110 | |
Software & Services - 12.9% | | | | | |
Akamai Technologies, Inc. | | | | 93,023 | b | 8,379,512 | |
Confluent, Inc., Cl. A | | | | 1,005,676 | b | 29,697,612 | |
CyberArk Software Ltd. | | | | 51,418 | a,b | 14,058,710 | |
HubSpot, Inc. | | | | 49,490 | b | 29,188,707 | |
| | | | | | | |
|
Description | | | | Shares | | Value ($) | |
Common Stocks - 96.2% (continued) | | | | | |
Software & Services - 12.9% (continued) | | | | | |
JFrog Ltd. | | | | 606,272 | b | 22,765,514 | |
Klaviyo, Inc., Cl. A | | | | 898,626 | a,b | 22,366,801 | |
Monday.com Ltd. | | | | 98,439 | b | 23,700,174 | |
Shopify, Inc., Cl. A | | | | 371,834 | b | 24,559,636 | |
| | | | 174,716,666 | |
Technology Hardware & Equipment - 2.2% | | | | | |
Calix, Inc. | | | | 396,000 | b | 14,030,280 | |
Pure Storage, Inc., Cl. A | | | | 256,446 | b | 16,466,398 | |
| | | | 30,496,678 | |
Total Common Stocks (cost $926,353,478) | | | | 1,304,422,491 | |
| | | | | | | |
Private Equity - 1.8% | | | | | |
Communication Services - .3% | | | | | |
Fundbox, Ser. D | | | | 702,664 | b,c | 3,513,320 | |
Food, Beverage & Tobacco - .6% | | | | | |
Supplying Demand, Inc., Ser. E | | | | 497,558 | b,c | 7,458,394 | |
Information Technology - .3% | | | | | |
Locus Robotics, Ser. F | | | | 101,086 | b,c | 4,539,772 | |
Pharmaceuticals, Biotechnology & Life Sciences - .5% | | | | | |
Aspen Neuroscience, Ser. B | | | | 1,963,167 | b,c | 6,537,346 | |
Software & Services - .1% | | | | | |
Roofstock, Ser. H | | | | 346,123 | b,c | 1,869,064 | |
Total Private Equity (cost $34,978,403) | | | | 23,917,896 | |
| | | | Number of Rights | | | |
Rights - .0% | | | | | |
Health Care Equipment & Services - .0% | | | | | |
Abiomed, Inc. expiring 12/31/2049 (cost $0) | | | | 160,644 | c | 163,857 | |
| | 1-Day Yield (%) | | | | | |
Investment Companies - 1.5% | | | | | |
Registered Investment Companies - 1.5% | | | | | |
Dreyfus Institutional Preferred Government Plus Money Market Fund, Institutional Shares (cost $20,549,965) | | 5.42 | | 20,549,965 | d | 20,549,965 | |
| | | | | | | |
Investment of Cash Collateral for Securities Loaned - 3.0% | | | | | |
Registered Investment Companies - 3.0% | | | | | |
Dreyfus Institutional Preferred Government Plus Money Market Fund, Institutional Shares (cost $41,047,433) | | 5.42 | | 41,047,433 | d | 41,047,433 | |
Total Investments (cost $1,022,929,279) | | 102.5% | | 1,390,101,642 | |
Liabilities, Less Cash and Receivables | | (2.5%) | | (34,247,549) | |
Net Assets | | 100.0% | | 1,355,854,093 | |
ADR—American Depositary Receipt
STATEMENT OF INVESTMENTS (Unaudited) (continued)
a Security, or portion thereof, on loan. At June 30, 2024, the value of the fund’s securities on loan was $125,045,627 and the value of the collateral was $127,980,849, consisting of cash collateral of $41,047,433 and U.S. Government & Agency securities valued at $86,933,416. In addition, the value of collateral may include pending sales that are also on loan.
b Non-income producing security.
c The fund held Level 3 securities at June 30, 2024. These securities were valued at $24,081,753 or 1.8% of net assets.
d Investment in affiliated issuer. The investment objective of this investment company is publicly available and can be found within the investment company’s prospectus.
The following is a summary of the inputs used as of June 30, 2024 in valuing the fund’s investments:
| | | | | | |
| Level 1-Unadjusted Quoted Prices | Level 2- Other Significant Observable Inputs | | Level 3-Significant Unobservable Inputs | Total | |
Assets ($) | | |
Investments in Securities:† | | |
Equity Securities - Common Stocks | 1,304,422,491 | - | | - | 1,304,422,491 | |
Equity Securities - Private Equity | - | - | | 23,917,896 | 23,917,896 | |
Investment Companies | 61,597,398 | - | | - | 61,597,398 | |
Rights | - | - | | 163,857 | 163,857 | |
† See Statement of Investments for additional detailed categorizations, if any.
The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the exclusive reference of authoritative U.S. generally accepted accounting principles (“GAAP”) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal laws are also sources of authoritative GAAP for SEC registrants. The fund is an investment company and applies the accounting and reporting guidance of the FASB ASC Topic 946 Financial Services-Investment Companies. The fund’s financial statements are prepared in accordance with GAAP, which may require the use of management estimates and assumptions. Actual results could differ from those estimates.
The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price). GAAP establishes a fair value hierarchy that prioritizes the inputs of valuation techniques used to measure fair value. This hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
Additionally, GAAP provides guidance on determining whether the volume and activity in a market has decreased significantly and whether such a decrease in activity results in transactions that are not orderly. GAAP requires enhanced disclosures around valuation inputs and techniques used during annual and interim periods.
Various inputs are used in determining the value of the fund’s investments relating to fair value measurements. These inputs are summarized in the three broad levels listed below:
Level 1—unadjusted quoted prices in active markets for identical investments.
Level 2—other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.).
Level 3—significant unobservable inputs (including the fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. Valuation techniques used to value the fund’s investments are as follows:
The Trust’s Board of Trustees (the “Board”) has designated the Adviser as the fund’s valuation designee to make all fair value determinations with respect to the fund’s portfolio investments, subject to the Board’s oversight and pursuant to Rule 2a-5 under the Act.
Investments in equity securities are valued at the last sales price on the securities exchange or national securities market on which such securities are primarily traded. Securities listed on the National Market System for which market quotations are available are valued at the official closing price or, if there is no official closing price that day, at the last sales price. For open short positions, asked prices are used for valuation purposes. Bid price is used when no asked price is available. Registered investment companies that are not traded on an exchange are valued at their net asset value. All of the preceding securities are generally categorized within Level 1 of the fair value hierarchy.
Securities not listed on an exchange or the national securities market, or securities for which there were no transactions, are valued at the average of the most recent bid and asked prices. U.S. Treasury Bills are valued at the mean price between quoted bid prices and asked prices by an independent pricing service (the “Service”) approved by the Board Members (“Board”). These securities are generally categorized within Level 2 of the fair value hierarchy.The Service’s procedures are reviewed by BNY Mellon under the general supervision of the Board.
Fair valuing of securities may be determined with the assistance of a pricing service using calculations based on indices of domestic securities and other appropriate indicators, such as prices of relevant American Depository Receipts and futures. Utilizing these techniques may result in transfers between Level 1 and Level 2 of the fair value hierarchy.
When market quotations or official closing prices are not readily available, or are determined not to accurately reflect fair value, such as when the value of a security has been significantly affected by events after the close of the exchange or market on which the security is principally traded (for example, a foreign exchange or market), but before the fund calculates its net asset value, the fund may value these investments at fair value as determined in accordance with the procedures approved by the Board. Certain factors may be considered when fair valuing investments such as: fundamental analytical data, the nature and duration of restrictions on disposition, an evaluation of the forces that influence the market in which the securities are purchased and sold, and public trading in similar securities of the issuer or comparable issuers. These securities are either categorized within Level 2 or 3 of the fair value hierarchy depending on the relevant inputs used.
For securities where observable inputs are limited, assumptions about market activity and risk are used and such securities are generally categorized within Level 3 of the fair value hierarchy.
Pursuant to a securities lending agreement with The Bank of New York Mellon, a subsidiary of BNY Mellon and an affiliate of BNY Mellon Investment Adviser, Inc., the fund may lend securities to qualified institutions. It is the fund’s policy that, at origination, all loans are secured by collateral of at least 102% of the value of U.S. securities loaned and 105% of the value of foreign securities loaned. Collateral equivalent to at least 100% of the market value
of securities on loan is maintained at all times. Collateral is either in the form of cash, which can be invested in certain money market mutual funds managed by BNY Mellon Investment Adviser Inc., or U.S. Government and Agency securities. The fund is entitled to receive all dividends, interest and distributions on securities loaned, in addition to income earned as a result of the lending transaction. Should a borrower fail to return the securities in a timely manner, The Bank of New York Mellon is required to replace the securities for the benefit of the fund or credit the fund with the market value of the unreturned securities and is subrogated to the fund’s rights against the borrower and the collateral. Additionally, the contractual maturity of security lending transactions are on an overnight and continuous basis.
At June 30, 2024, accumulated net unrealized appreciation on investments was $367,172,363, consisting of $441,670,594 gross unrealized appreciation and $74,498,231 gross unrealized depreciation.
At June 30, 2024, the cost of investments for federal income tax purposes was substantially the same as the cost for financial reporting purposes (see the Statement of Investments).
Additional investment related disclosures are hereby incorporated by reference to the annual and semi-annual reports previously filed with the SEC on Form N-CSR.